Although a precise mechanism underlying the refractoriness to immune checkpoint inhibitors (ICIs) in patients with HCC remains unexplored, hormones, such as vascular endothelial growth factor (VEGF), could mediate such refractoriness. This evidence concerns the gene VEGFA and hepatocellular carcinoma.